2 Important information Forward-looking statements and other important information Third quarter 2025 results Roy Jakobs, Chief Executive Officer Charlotte Hanneman, Chief Financial Officer November 4, 2025 Table of contents | Third quarter 2025 performance | 4 | | --- | --- | | 2025 outlook | 19 | | Financial appendix | 23 | © Koninklijke Philips N.V. This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with ...

Core Insights - The company reported strong order intake and sales growth in Q3 2025, driven by AI-powered innovations and partnerships, particularly in North America [2][4] - Comparable order intake grew by 8%, while comparable sales increased by 3.3%, with margin expansion attributed to increased sales and productivity [4][8] - The company is focused on patient safety and quality, with significant advancements in minimally invasive care in Indonesia [3][4] Group and Segment Performance - Comparable order intake grew by 8% in Q3 2025, with sales amounting to EUR 4.3 billion, reflecting a 3% increase in comparable sales [4][8] - Free cash flow increased to EUR 172 million, with an operating cash flow of EUR 327 million [8] - Adjusted EBITA margin improved by 50 basis points to 12.3% of sales [8] Segment Highlights - Diagnosis & Treatment comparable sales grew by 1.3%, with an adjusted EBITA margin of 11.8%, down 80 basis points due to tariffs [5] - Connected Care comparable sales increased by 5.1%, with an adjusted EBITA margin improving by 410 basis points to 11.4% [5] - Personal Health comparable sales grew by 10.9%, with an adjusted EBITA margin increasing by 60 basis points to 17.1% [6] Innovation Highlights - The company launched the Lumea IPL in the US, which has seen strong consumer interest [9] - New radiation therapy breakthroughs were unveiled, including advanced CT scanners and helium-free MR technology [9] - The launch of next-generation cardiovascular ultrasound systems included 26 FDA-cleared AI applications, the most in the industry [9] Productivity Initiatives - Disciplined cost management and productivity initiatives delivered savings of EUR 222 million in the quarter [10] - The company is on track to achieve a three-year EUR 2.5 billion productivity program, with EUR 800 million of savings expected in 2025 [10] Outlook - The company reiterated its confidence in delivering the full-year 2025 outlook, with adjusted EBITA margin now expected at the upper end of the range [11][15] - Free cash flow is projected to be between EUR 0.2 billion and EUR 0.4 billion, factoring in ongoing Philips Respironics-related proceedings [15]

Core Insights - The company reported strong order intake and sales growth in Q3 2025, driven by AI-powered innovations and partnerships, particularly in North America [2][4] - Comparable order intake grew by 8%, while comparable sales increased by 3.3%, with margin expansion attributed to increased sales and productivity [4][8] - The company is focused on patient safety and quality, with significant milestones achieved in expanding access to advanced care in Indonesia [3][4] Group and Segment Performance - Comparable order intake grew by 8% in Q3 2025, with sales amounting to EUR 4.3 billion, reflecting a 3% increase in comparable sales [4][8] - Free cash flow increased to EUR 172 million, and adjusted EBITA margin rose by 50 basis points to 12.3% of sales [8] - Diagnosis & Treatment segment saw a 1.3% growth in comparable sales, while Connected Care and Personal Health segments grew by 5.1% and 10.9%, respectively [5][6] Innovation Highlights - The company launched several new products, including the Lumea IPL hair removal system and advanced radiation therapy systems, which have received strong consumer interest [9] - The introduction of next-generation cardiovascular ultrasound systems included 26 FDA-cleared AI applications, marking a significant advancement in the industry [9] Productivity and Cost Management - Disciplined cost management and productivity initiatives resulted in savings of EUR 222 million in the quarter, contributing to the company's three-year EUR 2.5 billion productivity program [10] Outlook - The company reiterated its confidence in achieving the full-year 2025 outlook, with expectations for adjusted EBITA margin now toward the upper end of the range [11][15]